Research programme: navicims - Parvus Therapeutics

Drug Profile

Research programme: navicims - Parvus Therapeutics

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Calgary
  • Developer Parvus Therapeutics
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Multiple sclerosis; Type 1 diabetes mellitus

Most Recent Events

  • 19 Apr 2017 Novartis in-licenses navacim technology from Parvus Therapeutics
  • 17 Feb 2016 Preclinical trials in Autoimmune disorders (Liver autoimmune disease) in Canada (unspecified route)
  • 17 Feb 2016 Preclinical trials in Multiple sclerosis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top